Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting technique

The present study evaluated the treatment efficacy of the vascular disrupting agents CA4P and OXi4503 in an orthotopically transplanted human renal cell carcinoma xenograft model (Caki-1). Experiments used vascular casting, vessel density assessments as well as tumour necrosis measurements to evalua...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2006-11, Vol.42 (17), p.3073-3078
Main Authors: Salmon, Howard W., Mladinich, Christopher, Siemann, Dietmar W.
Format: Article
Language:English
Subjects:
Angiogenesis Inhibitors - therapeutic use
Animals
Biological and medical sciences
CA4P
Caki-1
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - ultrastructure
Diphosphates - therapeutic use
Female
Humans
Kidney
Kidney Neoplasms - drug therapy
Kidney Neoplasms - ultrastructure
Medical sciences
Mice
Mice, Nude
Mouse
Neoplasm Transplantation
Neovascularization, Pathologic - pathology
Neovascularization, Pathologic - prevention & control
OXi4053
Pharmacology. Drug treatments
Renal cell carcinoma
Silicon
Stilbenes - therapeutic use
Transplantation, Heterologous
Tumors
Vascular targeting
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The present study evaluated the treatment efficacy of the vascular disrupting agents CA4P and OXi4503 in an orthotopically transplanted human renal cell carcinoma xenograft model (Caki-1). Experiments used vascular casting, vessel density assessments as well as tumour necrosis measurements to evaluate the efficacy of these agents. After treatment with either agent, assessment of the vascular casts showed an almost total eradication of tumour blood vessels. Histological evidence further supported this observation, showing extensive central tumour necrosis with only a small viable rim of tumour cells remaining at the periphery. These results suggest that vascular disrupting agents CA4P and OXi4503 may have utility in the treatment of renal cell carcinoma, an encouraging result given that current conventional therapies have been currently largely unsuccessful in managing this disease.
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2006.06.016